Damien M. Cronier

2.8k total citations · 2 hit papers
35 papers, 1.5k citations indexed

About

Damien M. Cronier is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Damien M. Cronier has authored 35 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 13 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Damien M. Cronier's work include Monoclonal and Polyclonal Antibodies Research (13 papers), Advanced Breast Cancer Therapies (10 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Damien M. Cronier is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (13 papers), Advanced Breast Cancer Therapies (10 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Damien M. Cronier collaborates with scholars based in United States, United Kingdom and Spain. Damien M. Cronier's co-authors include Edward M. Chan, Lawrence M. Gelbert, Rose T. Ajamie, Shufen Cai, Alfonso de Dios, Graham N. Wishart, Ilaria Conti, Robert Ilaria, Miriam Del Prado and Marı́a José Lallena and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Damien M. Cronier

35 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

2014 446 citations Lawrence M. Gelbert, Shufen Cai et al. Investigational New Drugs profile →
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

2016 436 citations William D. Tap, Robin L. Jones et al. The Lancet profile →

Peers

Countries citing papers authored by Damien M. Cronier

Since Specialization

Citations

This map shows the geographic impact of Damien M. Cronier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Damien M. Cronier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Damien M. Cronier more than expected).

Fields of papers citing papers by Damien M. Cronier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Damien M. Cronier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Damien M. Cronier. The network helps show where Damien M. Cronier may publish in the future.

Co-authorship network of co-authors of Damien M. Cronier

This figure shows the co-authorship network connecting the top 25 collaborators of Damien M. Cronier. A scholar is included among the top collaborators of Damien M. Cronier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Damien M. Cronier. Damien M. Cronier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors 2022 ·Investigational New Drugs ·Saiama N. Waqar, Clifford G. Robinson, Anthony J. Olszanski, Alexander I. Spira, (unknown), (unknown), (unknown), Hulin Jin, Ursula Hering, Damien M. Cronier, Marianna Grinberg, (unknown), Iván Díaz-Padilla, Jordan Berlin	34
2	Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC‐3G3) to patients with advanced soft tissue sarcoma 2019 ·Cancer Medicine ·Víctor M. Villalobos, Gary Mo, Mark Agulnik, Seth M. Pollack, Daniel A. Rushing, Arun S. Singh, Brian A. Van Tine, (unknown), (unknown), Wei Zhang, Ashwin Shahir, Damien M. Cronier	2
3	Exposure–response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma 2018 ·Cancer Chemotherapy and Pharmacology ·Robin L. Jones, Gary Mo, John R. Baldwin, Patrick Peterson, Robert Ilaria, Ilaria Conti, Damien M. Cronier, William D. Tap	9
4	A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients 2017 ·Clinical Pharmacokinetics ·Sonya C. Tate, (unknown), Palaniappan Kulanthaivel, Edward M. Chan, P. Kellie Turner, Damien M. Cronier	55
5	Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC 2017 ·Lung Cancer ·David E. Gerber, Paul Swanson, Ariel López-Chávez, Lucas Wong, Afshin Dowlati, Nathan A. Pennell, Damien M. Cronier, Amy Qin, Robert Ilaria, Jan Cosaert, Ashwin Shahir, Maria Q. Baggstrom	9
6	Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer 2017 ·Clinical Pharmacokinetics ·Gary Mo, John R. Baldwin, Debra Luffer‐Atlas, Robert Ilaria, Ilaria Conti, Michael Heathman, Damien M. Cronier	21
7	Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma 2016 ·Clinical Cancer Research ·Noopur Raje, Edward A. Faber, Paul G. Richardson, Gary J. Schiller, Raymond J. Hohl, Adam D. Cohen, Andres Forero, Susan P. Carpenter, Tuan S. Nguyen, Ilaria Conti, Christopher Kaiser, Damien M. Cronier, James E. Wooldridge, Kenneth C. Anderson	22
8	Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial breakdown → 2016 ·The Lancet ·William D. Tap, Robin L. Jones, Brian A. Van Tine, Bartosz Chmielowski, Anthony Elias, Douglas Adkins, Mark Agulnik, Matthew M. Cooney, Michael B. Livingston, Gregory Pennock, Meera Hameed, Gaurav Shah, Amy Qin, Ashwin Shahir, Damien M. Cronier, Robert Ilaria, Ilaria Conti, Jan Cosaert, Gary K. Schwartz	436
9	Exposure-response of olaratumab for survival outcomes and safety when combined with doxorubicin in soft tissue sarcoma (STS) patients 2016 ·Annals of Oncology ·Robin L. Jones, Gary Mo, John R. Baldwin, (unknown), Robert Ilaria, Ilaria Conti, Damien M. Cronier, William D. Tap	1
10	Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours 2016 ·British Journal of Cancer ·Sonya C. Tate, Teresa F. Burke, (unknown), Palaniappan Kulanthaivel, Richard P. Beckmann, Damien M. Cronier	12
11	Phase 2 study of tabalumab, a human anti‐B‐cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma 2016 ·British Journal of Haematology ·Noopur Raje, Philippe Moreau, Evangelos Terpos, Lotfi Benboubker, Norbert Grząśko, Sarah A. Holstein, Albert Oriol, Shang‐Yi Huang, Meral Beksaç, Kazimierz Kuliczkowski, (unknown), James E. Wooldridge, Ilaria Conti, Christopher Kaiser, Tuan S. Nguyen, Damien M. Cronier, Antonio Palumbo	38
12	Abstract CT145: A phase I open-label study to evaluate the effect of olaratumab on the pharmacokinetics (PK) of doxorubicin (Dox) in patients with advanced soft tissue sarcoma (STS) 2016 ·Cancer Research ·Víctor M. Villalobos, Mark Agulnik, Seth M. Pollack, Daniel A. Rushing, Arun S. Singh, Brian A. Van Tine, (unknown), (unknown), Damien M. Cronier	2
13	Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Modeling of the Antitumor Activity of LY2835219, a New Cyclin-Dependent Kinase 4/6 Inhibitor, in Mice Bearing Human Tumor Xenografts 2014 ·Clinical Cancer Research ·Sonya C. Tate, Shufen Cai, Rose T. Ajamie, Teresa F. Burke, Richard P. Beckmann, Edward M. Chan, Alfonso de Dios, Graham N. Wishart, Lawrence M. Gelbert, Damien M. Cronier	100
14	Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγRIIIa Patients with Previously Treated Follicular Lymphoma 2014 ·Leukemia & lymphoma ·Kristen N. Ganjoo, Sven de Vos, Brad Pohlman, Ian W. Flinn, Andres Forero‐Torres, Nathan Enas, Damien M. Cronier, Nam H. Dang, Kenneth A. Foon, Susan P. Carpenter, Christopher A. Slapak, Brian K. Link, Mitchell R. Smith, Markus Y. Mapara, James E. Wooldridge	28
15	Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine breakdown → 2014 ·Investigational New Drugs ·Lawrence M. Gelbert, Shufen Cai, Xi Lin, Concepción Sánchez‐Martínez, Miriam Del Prado, Marı́a José Lallena, Raquel Torres, Rose T. Ajamie, Graham N. Wishart, (unknown), Blake Lee Neubauer, Jamie Young, Edward M. Chan, Philip W. Iversen, Damien M. Cronier, Emiko L. Kreklau, Alfonso de Dios	446
16	Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with non-small cell lung cancer. 2014 ·Journal of Clinical Oncology ·Jonathan W. Goldman, Leena Gandhi, Amita Patnaik, Lee S. Rosen, John Hilton, Kyriakos P. Papadopoulos, Sara M. Tolaney, Muralidhar Beeram, Drew Rasco, Scott P. Myrand, Richard P. Beckmann, Palaniappan Kulanthaivel, Martin Frenzel, Damien M. Cronier, Edward M. Chan, Keith T. Flaherty, Patrick Y. Wen, Anthony W. Tolcher, Geoffrey I. Shapiro	26
17	Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma 2012 ·Clinical Cancer Research ·Andres Forero‐Torres, Sven de Vos, Brad Pohlman, (unknown), Damien M. Cronier, Nam H. Dang, Susan P. Carpenter, Barrett W. Allan, (unknown), Christopher A. Slapak, Mitchell R. Smith, Brian K. Link, James E. Wooldridge, Kristen N. Ganjoo	54
18	Phase 1 Study of Tabalumab, a Human Anti-BAFF Antibody and Bortezomib in Patients with Previously-Treated Multiple Myeloma 2012 ·Blood ·Noopur Raje, Edward A. Faber, Paul G. Richardson, Gary J. Schiller, Raymond J. Hohl, Adam D. Cohen, Andres Forero, Susan P. Carpenter, Damien M. Cronier, Christopher Kaiser, James E. Wooldridge, Kenneth C. Anderson	10
19	Abstract B233: Identification and characterization of LY2835219: A potent oral inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6) with broad in vivo antitumor activity. 2011 ·Molecular Cancer Therapeutics ·Lawrence M. Gelbert, Shufen Cai, Xi Lin, Concepción Sánchez‐Martínez, Miriam Del Prado, Marı́a José Lallena, Raquel Torres, Rose T. Ajamie, Emiko L. Kreklau, Graham N. Wishart, (unknown), Blake Lee Neubauer, Jamie Young, Edward M. Chan, (unknown), Damien M. Cronier, Alfonso de Dios	14
20	Phase I study of LY2469298, an Fc‐engineered humanized anti‐CD20 antibody, in patients with relapsed or refractory follicular lymphoma 2010 ·Cancer Science ·Kensei Tobinai, Michinori Ogura, Yukio Kobayashi, Toshiki Uchida, Takashi Watanabe, Takashi Oyama, Dai Maruyama, Tatsuya Suzuki, Masakazu Mori, Masanobu Kasai, Damien M. Cronier, James E. Wooldridge, Minori Koshiji	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact